TG Therapeutics Announced The Issuance Of Three US Additional Patents For Briumvi For Relapsing Forms Of Multiple Sclerosis That Can Be Administered In One-hour Infusion Following The Starting Dose
Author: Benzinga Newsdesk | February 27, 2024 08:34am